title: Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.
abstract: Immunotherapy by adoptive transfer of autologous tumour-infiltrating lymphocytes (TIL) shows promising clinical results for stage III (lymph nodes metastasis) melanoma patients, but some of them remain unresponsive. Here we analysed retrospectively the impact of resistance of melanoma cells to anti-proliferative cytokines on the clinical outcome of 24 TIL-treated metastatic melanoma patients. Patient relapse-free survival correlated significantly with Oncostatin M (OSM) and/or IL-6 sensitivity of melanoma cells, but not with interferon (IFN) gamma or tumour necrosis factor (TNF) alpha sensitivity. However, OSM/IL-6 sensitivity did not correlate with other known prognostic factors. Moreover, OSM and IL-6 were produced by TIL just before their injection to patients. In immunodeficient mice, OSM reduced human melanoma xenograft tumour growth, this effect being directly through inhibition of tumour cell proliferation rather than induction of apoptosis or necrosis. Thus, OSM/IL-6 resistance of melanoma cells appears to be a new escape mechanism to TIL treatment that could be added to the existing prognostic factors for early stage melanoma patients. This mechanism of action could be also relevant in other immunotherapy protocols, and could lead to better prognosis and anti-cancer treatments.
authors.affiliation: INSERM U892, Centre de Recherche en Cancérologie, Nantes F-44035, France. alinelacreusette@yahoo.fr
authors.forename: A
authors.initials: A
authors.lastname: Lacreusette
authors.forename: A
authors.initials: A
authors.lastname: Lartigue
authors.forename: J-M
authors.initials: JM
authors.lastname: Nguyen
authors.forename: I
authors.initials: I
authors.lastname: Barbieux
authors.forename: M-C
authors.initials: MC
authors.lastname: Pandolfino
authors.forename: F
authors.initials: F
authors.lastname: Paris
authors.forename: A
authors.initials: A
authors.lastname: Khammari
authors.forename: B
authors.initials: B
authors.lastname: Dréno
authors.forename: Y
authors.initials: Y
authors.lastname: Jacques
authors.forename: F
authors.initials: F
authors.lastname: Blanchard
authors.forename: A
authors.initials: A
authors.lastname: Godard
mesh_terms: D019264:Adoptive Transfer / Q000379:methods*; D000818:Animals; D015153:Blotting, Western / Q000379:methods; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism / Q000627:therapeutic use*; D008207:Lymphatic Metastasis; D016246:Lymphocytes, Tumor-Infiltrating / Q000378:metabolism / Q000637:transplantation*; D008545:Melanoma / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008819:Mice, Nude; D009367:Neoplasm Staging; D053683:Oncostatin M / Q000378:metabolism / Q000627:therapeutic use*; D019947:Receptors, Interleukin-6 / Q000378:metabolism; D053677:Receptors, Oncostatin M / Q000378:metabolism; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D023041:Xenograft Model Antitumor Assays
chemical_list: D015850:Interleukin-6; D019947:Receptors, Interleukin-6; D053677:Receptors, Oncostatin M; D053683:Oncostatin M